Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SELECTED FINANCIAL STATEMENT - ASSETS

SELECTED FINANCIAL STATEMENT - ASSETS

6 Months Ended

Jun. 30, 2023

Balance Sheet Related Disclosures [Abstract]

SELECTED FINANCIAL STATEMENT - ASSETS

NOTE 4 — SELECTED FINANCIAL STATEMENT — ASSETS

Inventories consisted of the following (in thousands):


	June 30, 2023			December 31, 2022
Raw materials and components	$	1,362		$	1,393
Work-in-process		224			513
Finished goods		5,198			5,428
Inventory reserve		(4,970	)		(4,955	)
Total inventories, net	$	1,814		$	2,379

Prepaid expenses and other current assets consisted of the following (in thousands):


	June 30, 2023		December 31, 2022
Prepaid insurance	$	328	$	598
Prepaid expenses		337		467
Other current assets		434		449
Total prepaid expenses and other current assets	$	1,099	$	1,514

Property and equipment consisted of the following (in thousands):


	June 30, 2023			December 31, 2022
Equipment	$	377		$	367
Leasehold improvements		39			39
Furniture and fixtures		99			99
Total property and equipment		515			505
Less: accumulated depreciation		(447	)		(430	)
Total property and equipment, net	$	68		$	75

During the three months ended June 30, 2023 and 2022, depreciation expense was approximately $9,000 and $10,000, respectively. During the six months ended June 30, 2023 and2022, depreciation expense was approximately $18,000 and $21,000, respectively.